Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis

Pediatric Rheumatology

Volumn 10, Issue , 2012, Pages

  Tebo, Anne E ^a,b   Jaskowski, Troy ^a   Davis, K W ^a   Whiting, April ^b   Clifford, Bronte ^b   Zeft, Andrew ^b   McNally, Bernadette ^b   Hill, Harry R ^a,b   Bohnsack, John ^b   Prahalad, Sampath ^c,d  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

Cyclic citrullinated peptide; Juvenile idiopathic arthritis; Rheumatoid arthritis; Serologic markers

Indexed keywords

ANTINUCLEAR ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RHEUMATOID FACTOR;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 84865403256     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-10-29     Document Type: Article

References (31)

1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004, 31:390-392.
2. Avcin T, Cimaz R, Falcini F, Zulian F, Martini G, Simonini G, et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2002, 61:608-611. 10.1136/ard.61.7.608, 1754144, 12079901.
3. Gabay C, Prieur AM, Meyer O. Occurrence of antiperinuclear, antikeratin, and anti-RA 33 antibodies in juvenile chronic arthritis. Ann Rheum Dis 1993, 52:785-789. 10.1136/ard.52.11.785, 1005189, 7504436.
4. Nesher G, Moore TL, Grisanti MW, el-Najdawi E, Osborn TG. Antiperinuclear factor in juvenile rheumatoid arthritis. Ann Rheum Dis 1992, 51:350-352. 10.1136/ard.51.3.350, 1004659, 1575580.
5. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62:2569-2581. 10.1002/art.27584, 20872595.
6. Padyukov L, Seielstad M, Ong RT, Ding B, Ronnelid J, Seddighzadeh M, et al. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 2011, 70:259-265. 10.1136/ard.2009.126821, 3015094, 21156761.
7. Brunner J, Sitzmann FC. The diagnostic value of anti-cyclic citrullinated peptide (CCP) antibodies in children with Juvenile Idiopathic Arthritis. Clin Exp Rheumatol 2006, 24:449-451.
8. Ferucci ED, Majka DS, Parrish LA, Moroldo MB, Ryan M, Passo M, et al. Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2005, 52:239-246. 10.1002/art.20773, 15641089.
9. Gilliam BE, Reed MR, Chauhan AK, Dehlendorf AB, Moore TL. Evidence of fibrinogen as a target of citrullination in IgM rheumatoid factor-positive polyarticular juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2011, 9:8. 10.1186/1546-0096-9-8, 3071779, 21439056.
10. Gupta R, Thabah MM, Vaidya B, Gupta S, Lodha R, Kabra SK. Anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Indian J Pediatr 2010, 77:41-44. 10.1007/s12098-010-0006-4, 20135267.
11. Habib HM, Mosaad YM, Youssef HM. Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Immunol Invest 2008, 37:849-857. 10.1080/08820130802438057, 18991100.
12. Hromadnikova I, Stechova K, Pavla V, Hridelova D, Houbova B, Voslarova S, et al. Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Autoimmunity 2002, 35:397-401. 10.1080/0891693021000014970, 12568120.
13. Kasapcopur O, Altun S, Aslan M, Karaarslan S, Kamburoglu-Goksel A, Saribas S, et al. Diagnostic accuracy of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2004, 63:1687-1689. 10.1136/ard.2003.019331, 1754844, 15547097.
14. Kuna AT, Lamot L, Miler M, Harjacek M, Simundic AM, Vrkic N. Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis. Clin Chem Lab Med 2009, 47:1525-1530.
15. Kwok JS, Hui KH, Lee TL, Wong W, Lau YL, Wong RW, et al. Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol 2005, 34:359-366. 10.1080/03009740510026634, 16234183.
16. Low JM, Chauhan AK, Kietz DA, Daud U, Pepmueller PH, Moore TL. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. J Rheumatol 2004, 31:1829-1833.
17. Ozawa R, Inaba Y, Mori M, Hara R, Kikuchi M, Higuchi R, et al. Definitive differences in laboratory and radiological characteristics between two subtypes of juvenile idiopathic arthritis: systemic arthritis and polyarthritis. Mod Rheumatol 2011, 22:558-564.
18. Syed RH, Gilliam BE, Moore TL. Prevalence and significance of isotypes of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2008, 67:1049-1051.
19. van Rossum M, van Soesbergen R, de Kort S, ten Cate R, Zwinderman AH, de Jong B, et al. Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol 2003, 30:825-828.
20. Morbach H, Dannecker H, Kerkau T, Girschick HJ. Prevalence of antibodies against mutated citrullinated vimentin and cyclic citrullinated peptide in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2010, 28:800.
21. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48:2741-2749. 10.1002/art.11223, 14558078.
22. Plenge RM. Recent progress in rheumatoid arthritis genetics: one step towards improved patient care. Curr Opin Rheumatol 2009, 21:262-271. 10.1097/BOR.0b013e32832a2e2d, 19365266.
23. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006, 54:38-46. 10.1002/art.21575, 16385494.
24. Havemose-Poulsen A, Westergaard J, Stoltze K, Skjodt H, Danneskiold-Samsoe B, Locht H, et al. Periodontal and hematological characteristics associated with aggressive periodontitis, juvenile idiopathic arthritis, and rheumatoid arthritis. J Periodontol 2006, 77:280-288. 10.1902/jop.2006.050051, 16460255.
25. Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P, et al. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 2008, 58:3009-3019. 10.1002/art.23936, 18821669.
26. Lundberg K, Wegner N, Yucel-Lindberg T, Venables PJ. Periodontitis in RA-the citrullinated enolase connection. Nat Rev Rheumatol 2010, 6:727-730. 10.1038/nrrheum.2010.139, 20820197.
27. Toussirot E, Roudier J. Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: an update. Joint Bone Spine 2007, 74:418-426. 10.1016/j.jbspin.2007.05.001, 17625943.
28. Prahalad S, Thompson SD, Conneely KN, Jiang Y, Leong T, Prozonic J, et al. Hierarchy of risk of childhood-onset rheumatoid arthritis conferred by HLA-DRB1 alleles encoding the shared epitope. Arthritis Rheum 2012, 64:925-930.
29. Hassfeld W, Steiner G, Hartmuth K, Kolarz G, Scherak O, Graninger W, et al. Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum 1989, 32:1515-1520. 10.1002/anr.1780321204, 2597207.
30. Nesher G, Wilson VK, Moore TL, Osborn TG, Hanna VE. Antiperinuclear and anti-RA33 antibodies in juvenile chronic arthritis. Ann Rheum Dis 1994, 53:282-283. 1005313, 8203963.
31. Tomoum HY, Mostafa GA, El-Shahat EM. Autoantibody to heterogeneous nuclear ribonucleoprotein-A2 (RA33) in juvenile idiopathic arthritis: clinical significance. Pediatr Int 2009, 51:188-192. 10.1111/j.1442-200X.2008.02667.x, 19405913.